Safety of romiplostim and eltrombopag for children with immune thrombocytopenia: a pharmacovigilance study of the FDA adverse event reporting system database-Reference-Cited by-同舟云学术

Safety of romiplostim and eltrombopag for children with immune thrombocytopenia: a pharmacovigilance study of the FDA adverse event reporting system database

Published:2023-02-23 Issue:8 Volume:22 Page:707-714
ISSN:1474-0338
Container-title:Expert Opinion on Drug Safety
language:en
Short-container-title:Expert Opinion on Drug Safety

Author:

Fang Qiongtong¹^ORCID,Huang Fuqiang²,Liang Jiabi¹,Chen Yishen¹,Li Cheng¹,Zhang Meirong¹,Wu Xinrong³,Luo Wenji¹

Affiliation:

1. Department of Pharmacy, the Fifth Affiliated Hospital of Sun Yat-Sen University, Zhuhai, Guangdong, China

2. Department of Biostatistics, School of Public Health, Southern Medical University, Guangzhou, Guangdong, China

3. Department of Pharmacy, General Hospital of Southern Theatre Command of PLA, Guangzhou, Guangdong, China

Publisher

Informa UK Limited

Subject

Pharmacology (medical),General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/14740338.2023.2182288

Reference42 articles.

1. Identifying and treating refractory ITP: difficulty in diagnosis and role of combination treatment

2. Pathogenesis and Therapeutic Mechanisms in Immune Thrombocytopenia (ITP)

3. Eltrombopag versus romiplostim in treatment of children with persistent or chronic immune thrombocytopenia: a systematic review incorporating an indirect-comparison meta-analysis

4. Nplate™ (Romiplostim). FDA. 2022. [cited 2022 Sep 13]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/125268s172lbl.pdf.

5. PROMACTA® (eltrombopag) tablets. FDA. 2022. [cited 2022 Sep 13]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/022291s033,207027s015lbl.pdf.

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Experimental Validation a Method for Assessing Neutralizing Antibodies of Romiplostim in Human Plasma;Drug development & registration;2024-02-20